Selank has limited human comparative literature and a larger mechanistic narrative around GABA signaling. The human reports are small, mostly Russian-language, and do not establish broad international clinical efficacy.
Evidence at a glance
- A 2008 report compared 30 Selank participants with 32 receiving medazepam in generalized anxiety disorder or neurasthenia.
- A 2014 report compared Selank and phenazepam in 60 people with anxiety or somatoform diagnoses.
- A 2016 rat study measured 84 neurotransmission genes and found 45 altered at 1 hour and 22 at 3 hours; that is mechanistic animal evidence.
Study record
The 2008 abstract reports similar anxiolytic effects between groups and changes in serum enkephalin activity. The record available through PubMed does not provide the full randomization, masking, attrition and adverse-event detail expected from a modern confirmatory trial.
Results in context
The 2014 comparison reported anxiolytic and mild nootropic effects and stated that the effect persisted for one week after the last administration. Again, the English-accessible record is an abstract-level report and should not be expanded beyond the stated population and endpoints.
In rats, Selank and GABA produced correlated short-term gene-expression changes in frontal cortex. A related IMR-32 cell study did not find direct Selank-only changes in the same gene panel, illustrating why a proposed GABA mechanism should remain a hypothesis rather than a settled clinical explanation.
What the evidence cannot establish
Small studies and limited accessible methods make bias and generalizability difficult to judge.
Different comparators and diagnoses should not be pooled into one efficacy percentage.
Gene-expression findings in rats and neuroblastoma cells do not establish symptom benefit in people.
Sources & editorial method
This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.
4 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, sample size, model/population limits and regulatory scope are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Selank versus medazepam in GAD and neurastheniaSmall 62-person Russian-language report; PMID 18454096.
- Selank versus phenazepam clinical comparisonSmall 60-person Russian-language report; PMID 25176261.
- Selank affects expression of genes involved in GABAergic neurotransmissionExperimental study. 2016. PMID 26924987.
- PubChem Selank recordSequence, formula, molecular weight and synonyms; CID 11765600.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
